Clinicopathologic correlations and short-term prognosis in musculoskeletal sarcoma with c-myc oncogene amplification.
The prognostic significance of c-myc oncogene amplification was investigated in a series of 44 patients with musculoskeletal malignancy. There were 21 bone tumors and 23 soft tissue sarcomas. Amplification of the c-myc oncogene was detected in 11 tumors: 4 bone tumors and 7 soft tissue sarcomas. In 9 of the 11 myc-amplified tumors a high grade of malignancy was revealed histologically. The relative frequency of c-myc amplification was higher in grade IV tumors. After a mean follow-up of 18 months, 6 of 11 patients with c-myc-amplified tumors and 12 of 33 patients with nonamplified tumors either exhibited recurrence or died of tumor disease. Both 3-year estimated overall survival and disease-free survival probability were lower for patients with myc-amplified tumors. Amplification of the c-myc oncogene was associated with poor short-term prognosis. Although gene amplification was encountered sporadically in musculoskeletal sarcomas, the reported data suggest that analysis of c-myc may provide valid information on prognosis.
Barrios
C
C
Department of Orthopedics, Karolinska Hospital, Stockholm, Sweden.
Castresana
J S
JS
Kreicbergs
A
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001859:Bone Neoplasms / Q000235:genetics* / Q000401:mortality*; D005260:Female; D005784:Gene Amplification; D016259:Genes, myc; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012509:Sarcoma / Q000235:genetics* / Q000401:mortality*; D016019:Survival Analysis